![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-desktop-headergif-65408.gif)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-mobile-headergif-45399.gif)
Active Filter(s):
Details:
Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Preclinical Product Type: Small molecule
Recipient: Quantum Genomics
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration December 15, 2020